- Home
- VMD vs EDIT Comparison
VMD vs EDIT Comparison
Compare VMD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- EDIT
- Stock Information
- Founded
- VMD 2006
- EDIT 2013
- Country
- VMD United States
- EDIT United States
- Employees
- VMD N/A
- EDIT N/A
- Industry
- VMD
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VMD
- EDIT Health Care
- Exchange
- VMD Nasdaq
- EDIT Nasdaq
- Market Cap
- VMD 280.4M
- EDIT 269.8M
- IPO Year
- VMD N/A
- EDIT 2016
- Fundamental
- Price
- VMD $6.34
- EDIT $2.44
- Analyst Decision
- VMD
- EDIT Buy
- Analyst Count
- VMD 0
- EDIT 10
- Target Price
- VMD N/A
- EDIT $4.13
- AVG Volume (30 Days)
- VMD 145.3K
- EDIT 2.2M
- Earning Date
- VMD 11-05-2025
- EDIT 11-10-2025
- Dividend Yield
- VMD N/A
- EDIT N/A
- EPS Growth
- VMD 35.92
- EDIT N/A
- EPS
- VMD 0.34
- EDIT N/A
- Revenue
- VMD $254,794,000.00
- EDIT $46,383,000.00
- Revenue This Year
- VMD $19.22
- EDIT N/A
- Revenue Next Year
- VMD $17.51
- EDIT N/A
- P/E Ratio
- VMD $18.62
- EDIT N/A
- Revenue Growth
- VMD 18.89
- EDIT N/A
- 52 Week Low
- VMD $5.93
- EDIT $0.91
- 52 Week High
- VMD $9.05
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- VMD 43.38
- EDIT 34.25
- Support Level
- VMD $6.18
- EDIT $2.45
- Resistance Level
- VMD $6.50
- EDIT $2.69
- Average True Range (ATR)
- VMD 0.20
- EDIT 0.20
- MACD
- VMD -0.01
- EDIT -0.02
- Stochastic Oscillator
- VMD 47.73
- EDIT 12.99
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.